CD8A and neoplasm: Kim et al. evaluated the combined effect of anti-PD-L1 and RT by using murine HCa-1 cells and found that this combined therapy resulted in the restoration of CD8+ T-cell functions, significantly suppressed tumor growth, and improved the survival rate compared to the anti-PD-L1 or RT alone group 44.